- Title
- Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma?
- Creator
- McDonald, Vanessa M.; Urroz, Paola D.; Bajc, Marika; Rutherford, Natalie; Brooker, Bree; Gibson, Peter G.
- Relation
- Respirology Case Reports Vol. 9, Issue 3, no. e00717
- Publisher Link
- http://dx.doi.org/10.1002/rcr2.717
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2021
- Description
- Monoclonal antibody therapies are effective for many but not all people with severe asthma. Precision medicine guides treatment selection using biomarkers to select patients most likely to respond according to their inflammatory endotypes. However, when assessing response to treatment, greater precision is required. We report a case series describing treatment response to mepolizumab in four severe asthma patients, assessed by traditional methods and with objective ventilation/perfusion single photon emission computed tomography (V-P SPECT). In this series, patients with severe asthma received mepolizumab treatment with clinical outcomes recorded at commencement and at approximately 16 weeks post-treatment initiation. V-P SPECT imaging was performed before and after treatment to determine ventilation heterogeneity and perfusion, and its ability to assess treatment responsiveness. V-P SPECT shows promise as an objective measure to assess lung ventilation and perfusion to observe and assess responsiveness to mepolizumab. With quantification, this measure may allow better precision in determining treatment improvements.
- Subject
- mepolizumab; severe asthma; treatable traits; ventilation; V-P SPECT; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1461691
- Identifier
- uon:46276
- Identifier
- ISSN:2051-3380
- Rights
- © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-No Derivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made (https://creativecommons.org/licenses/by-nc/4.0/).
- Language
- eng
- Full Text
- Reviewed
- Hits: 1508
- Visitors: 1822
- Downloads: 317
Thumbnail | File | Description | Size | Format | |||
---|---|---|---|---|---|---|---|
View Details Download | ATTACHMENT02 | Publisher version (open access) | 467 KB | Adobe Acrobat PDF | View Details Download |